Blinatumomab Trimer Formation
Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…
Certara2024 年 9 月 16 日
4 ways that mechanistic modeling accelerates bispecific (and multispecific) antibody drug development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
Certara2024 年 9 月 12 日
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)
Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…
Certara2024 年 9 月 9 日
Optimizing Avidity of Bispecific Drugs
Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…
Certara2024 年 9 月 9 日
Effects of Tissue Targeting Bispecifics on Therapeutic Window
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…
Certara2024 年 9 月 9 日
Optimizing Clinical Development: Saving Time and Costs
战略机械建模解决方案可帮助免疫肿瘤生物技术加速其新型疗法的临床开发。
Certara2024 年 8 月 16 日
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology
Bispecific T-cell Engagers (TCEs) are promising anti-cancer treatments that bind to both the CD3 receptors…
Certara2024 年 7 月 23 日
Gene therapy based precision medicine therapeutics: Clinical pharmacology & translational science considerations
The era of gene therapy may have started a couple of decades ago, but approvals…
Certara2021 年 8 月 13 日
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines
Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due…
Certara2021 年 7 月 31 日
